Compare HLNE & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HLNE | GPCR |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2017 | 2023 |
| Metric | HLNE | GPCR |
|---|---|---|
| Price | $88.41 | $36.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $156.78 | $103.17 |
| AVG Volume (30 Days) | 439.9K | ★ 810.3K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 41.64 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $758,993,000.00 | N/A |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $15.81 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $71.88 | $23.61 |
| 52 Week High | $155.66 | $94.90 |
| Indicator | HLNE | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 28.14 |
| Support Level | $86.48 | N/A |
| Resistance Level | $107.09 | $41.50 |
| Average True Range (ATR) | 3.68 | 2.47 |
| MACD | -2.01 | -0.82 |
| Stochastic Oscillator | 12.36 | 11.92 |
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.